Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats

Neuroscience

Volumn 81, Issue 1, 1997, Pages 141-149

  Guyot, M C ^a   Palfi, S ^a   Stutzmann, J M ^b   Maziere M ^a   Hantraye, P ^a   Brouillet, E ^a  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b CRVA   (France)

Author keywords

Excitotoxicity; Malonate; Motor behaviour; Neuroprotection; Succinate dehydrogenase

Indexed keywords

3 NITROPROPIONIC ACID; MALONIC ACID; RILUZOLE; SUCCINATE DEHYDROGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; BRAIN TOXICITY; DATA ANALYSIS; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG MECHANISM; HISTOCHEMISTRY; MALE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RAT; STATISTICAL ANALYSIS;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CORPUS STRIATUM; INJECTIONS, INTRAPERITONEAL; MALE; MALONATES; MICROINJECTIONS; MOVEMENT DISORDERS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; NITRO COMPOUNDS; PROPIONIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY; RILUZOLE; SUCCINATE DEHYDROGENASE; SURVIVAL ANALYSIS;

EID: 0030764219     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(97)00192-9     Document Type: Article

References (32)

1. Ackrell B. A., Kearney E. B., Singer T. P. Mammalian succinate dehydrogenase. Meth. Enzym. 53:1978;466-483.
2. Beal M. F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38:1995;357-366.
3. Beal M. F., Brouillet E., Jenkins B. G., Ferrante R. J., Kowall N. W., Miller J. M., Storey E., Srivastava R., Rosen B. R., Hyman B. T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13:1993;4181-4192.
4. Bederson J. B., Pitts L. H., Germano S. M., Nishimura M. C., Davis R. L., Bartkowski H. M. 2,3,5-Triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke. 17:1986;1304-1308.
5. + channels in myelinated nerve fibre. Pflügers Arch. 361:1991;1-7.
6. Bensimon G., Lacomblez L., Meininger V., Group A. R. S. A controlled trial of riluzole in amyotrophic lateral sclerosis. New Engl. J. Med. 330:1994;585-591.
7. Borlongan C. V., Koutouzis T. K., Randall T. S., Freeman T. B., Cahill D. W., Sanberg P. R. Systemic 3-nitropropionic acid, behavioral deficits and striatal damage in adult rats. Brain Res. Bull. 36:1995;549-556.
8. Brouillet E., Guyot M. C., Dolan R., Mazière M., Hantraye P. Histological and behavioural effects of chronic 3-nitropropionic acid treatment in old rats. Soc. Neurosci. Abstr. 20:1994;1255.
9. Brouillet E., Hantraye P., Ferrante R. J., Dolan R., Kowall N. W., Beal M. F. Chronic mitochrondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. natn. Acad. Sci. U.S.A. 92:1995;7105-7109.
10. Brouillet E., Jenkins B. G., Hyman B. T., Ferrante R. J., Kowall N. W., Srivastava R., Roy D. S., Rosen B. R., Beal M. F. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J. Neurochem. 60:1993;356-359.
11. Chéramy A., Barbeito L., Godeheu G., Glowinski J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci. Lett. 147:1992;209-212.
12. Debono M. W., Le Guern J., Canton T., Doble A., Pradier L. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur. J. Pharmac. 235:1993;283-289.
13. 3H]aspartate release from cultured cerebellar granule cells. Neurosci. Lett. 140:1992;251-254.
14. Estevez A. G., Stutzmann J. M., Barbeito L. Protective effect of riluzole on excitatory amino acid-mediated neurotoxicity in motoneuron-enriched cultures. Eur. J. Pharmac. 280:1994;47-53.
15. Girdlestone D., Dupuy A., Roy-Contencin L., Escande D. Riluzole antagonizes excitatory amino acid-evoked firing in rat facial motoneurons in vivo. Br. J. Pharmac. 97:1989;583.
16. Greene J. G., Greenamyre J. T. Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate. J. Neurochem. 64:1995;430-436.
17. Guyot M. C., Hantraye P., Dolan R., Palfi S., Mazière M., Brouillet E. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience. 79:1996;45-56.
18. Hubert J. P., Delumeau J. C., Glowinski J., Prémont J., Doble A. Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells, evidence for a dual mechanism of action. Br. J. Pharmac. 113:1994;261-267.
19. Koutouzis T. K., Borlongan C. V., Scorcia T., Creese I., Cahill D. W., Freeman T. B., Sanberg P. R. Systemic 3-nitropropionic acid, long-term effects on locomotor behavior. Brain Res. 646:1994;242-246.
20. Lacomblez L., Bensimon G., Leigh N., Guillet P., Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. The Lancet. 347:1996;1425-1431.
21. MacIver M. B., Amagasu S. M., Mikulec A. A., Monroe F. A. Riluzole anesthesia, use-dependent block of presynaptic glutamate fibers. Anesthesiology. 85:1996;626-634.
22. Martin D., Thompson M. A., Nadler J. V. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur. J. Pharmac. 250:1993;473-476.
23. Mary V., Wahl F., Stutzmann J. M. Effect of riluzole on quinolinate-induced neuronal damage in rats, comparison with blockers of glutamatergic neurotransmission. Neurosci. Lett. 201:1995;92-96.
24. Novelli A., Reilly J. A., Lysko P. G., Henneberry R. C. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. 451:1988;205-212.
25. Palfi S., Ferrante R. J., Brouillet E., Beal M. F., Dolan R., Guyot M. C., Peschanski M., Hantraye P. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's Disease. J. Neurosci. 16:1996;3019-3025.
26. Palfi S., Guyot M. C., Hantraye P., Altairac S., Brouillet E. Characterization of the inhibition of brain succinate dehydrogenase after systemic administration of 3-nitropropionic acid. Soc. Neurosci. Abstr. 22:1996;1905.
27. Palfi S., Riche D., Brouillet E., Guyot M. C., Wahl F., Mary V., Peschanski M., Stutzmann J. M. and Hantraye P. (1996) Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. Expl Neurol. (in press).
28. Riddle D., Richards A., Zsuppan F., Purves D. Growth of the rat somatic sensory cortex and its constituent parts during postnatal development. J. Neurosci. 12:1992;3509-3524.
29. Stutzmann J. M. and Doble A., Blockade of glutamatergic transmission and neuroprotection, the strange case of riluzole. (1994) In Neurodegenerative Diseases (eds Jolles G. and Stutzmann J. M.), pp. 205-214. Academic Press Ltd., London.
30. Tsaï C., Steel D. J., McPherson S., Taylor C. A., Wood P. L. and Lehmann J. (1987) PK26124 is not a competitive antagonist at NMDA-type receptors. In Excitatory Amino Acid Transmission (eds Hicks P. and Lodge D. A. M. H.). pp. 79-82. A. R. Liss, London.
31. Turski L., Turski W. A. Towards an understanding of the role of glutamate in neurodegenerative disorders, energy metabolism and neuropathology. Experientia. 49:1993;1064-1072.
32. Zeevalk G. D., Derr-Yellin E., Nicklas W. J. NMDA receptor involvement in toxicity to dopamine neurons in vitro caused by the succinate dehydrogenase inhibitor 3-nitropropionic acid. J. Neurochem. 64:1995;455-458.